Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.

[1]  Howard Y. Chang,et al.  Enhanced T cell effector activity by targeting the Mediator kinase module , 2022, Science.

[2]  Won-Sik Shin,et al.  Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma , 2022, International journal of molecular sciences.

[3]  S. Kaech,et al.  SnapShot: Cancer immunoediting , 2022, Cell.

[4]  Nathan E. Reticker-Flynn,et al.  Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy , 2022, eLife.

[5]  Won-Sik Shin,et al.  Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function , 2022, Cancers.

[6]  Azam Bozorgi,et al.  Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects , 2022, Cellular Oncology.

[7]  B. Shi,et al.  Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling. , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  D. Kufe,et al.  Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression , 2022, International journal of molecular sciences.

[9]  Hao Zhang,et al.  The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook , 2022, Frontiers in Immunology.

[10]  B. Deleuran,et al.  Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events , 2022, Frontiers in Immunology.

[11]  C. June,et al.  Engineered cellular immunotherapies in cancer and beyond , 2022, Nature Medicine.

[12]  Abhishek Kumar,et al.  Whole-Exome Sequencing Identifies a Novel Germline Variant in PTK7 Gene in Familial Colorectal Cancer , 2022, International journal of molecular sciences.

[13]  L. Pączek,et al.  PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells , 2022, Journal for ImmunoTherapy of Cancer.

[14]  R. de Waal Malefyt,et al.  An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma , 2021, Science Translational Medicine.

[15]  S. Nunez-cruz,et al.  A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia , 2021, Science Translational Medicine.

[16]  S. Gottschalk,et al.  Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer , 2021, Journal for ImmunoTherapy of Cancer.

[17]  M. Stack,et al.  Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment , 2021, International journal of molecular sciences.

[18]  N. Jahchan,et al.  Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. , 2021, Cell reports.

[19]  Xingxu Huang,et al.  IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors. , 2021, Cancer letters.

[20]  P. Jänne,et al.  Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. , 2021, The New England journal of medicine.

[21]  R. Kalluri,et al.  Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.

[22]  Baoxia Liang,et al.  IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin , 2021, Journal of Hematology & Oncology.

[23]  Bao-ping Chen,et al.  Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer , 2021, Frontiers in Oncology.

[24]  E. Kubicka,et al.  Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells , 2021, Frontiers in Immunology.

[25]  Sherine F. Elsawa,et al.  Macrophage Polarization States in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[26]  G. Wertheim,et al.  Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Y. Rinkevich,et al.  Fibroblasts as confederates of the immune system , 2021, Immunological reviews.

[28]  Xiangxuan Zhao,et al.  Targeting Bcl-2 for cancer therapy. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[29]  M. Merad,et al.  MDSC: Markers, development, states, and unaddressed complexity. , 2021, Immunity.

[30]  A. Grothey,et al.  Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. , 2021, The Lancet. Oncology.

[31]  N. Xia,et al.  Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition , 2021, Cancer Immunology Research.

[32]  Stephanie A. Kazane,et al.  Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. , 2021, ACS synthetic biology.

[33]  K. Lehti,et al.  Mesothelin-Specific CAR T Cells Target Ovarian Cancer , 2021, Cancer Research.

[34]  C. Denkert,et al.  Breast cancer , 2021, The Lancet.

[35]  K. Rock,et al.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation , 2021, Frontiers in Immunology.

[36]  Jingnan Wang,et al.  Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity , 2021, Journal for ImmunoTherapy of Cancer.

[37]  Jianguo Wang,et al.  Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[38]  S. Schuster,et al.  Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. , 2021, The New England journal of medicine.

[39]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[40]  A. Titov,et al.  Adoptive Immunotherapy beyond CAR T-Cells , 2021, Cancers.

[41]  B. Becher,et al.  Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma , 2021, Nature Communications.

[42]  J. Briones,et al.  Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma , 2021, Clinical & translational immunology.

[43]  J. Serody,et al.  STING agonist promotes CAR T cell trafficking and persistence in breast cancer , 2020, The Journal of experimental medicine.

[44]  T. Webster,et al.  CAR-T cells: Early successes in blood cancer and challenges in solid tumors , 2020, Acta pharmaceutica Sinica. B.

[45]  Liangliang Wu,et al.  PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies , 2020, Frontiers in Immunology.

[46]  S. Albelda,et al.  Mesothelin-targeted CAR-T cell therapy for solid tumors , 2020, Expert opinion on biological therapy.

[47]  H. Bear,et al.  Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets , 2020, Breast Cancer Research.

[48]  J. Utikal,et al.  Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation , 2020, Journal for ImmunoTherapy of Cancer.

[49]  Jieyu Liu,et al.  Arsenic-induced HER2 promotes proliferation, migration and angiogenesis of bladder epithelial cells via activation of multiple signaling pathways in vitro and in vivo. , 2020, The Science of the total environment.

[50]  Wei-Lin Jin,et al.  The updated landscape of tumor microenvironment and drug repurposing , 2020, Signal Transduction and Targeted Therapy.

[51]  H. Grabsch,et al.  Gastric cancer , 2020, The Lancet.

[52]  Y. Chen,et al.  Engineering CAR-T Cells for Next-Generation Cancer Therapy. , 2020, Cancer cell.

[53]  Jiang F Zhong,et al.  Recent advances in CAR-T cell engineering , 2020, Journal of Hematology & Oncology.

[54]  Jian Cao,et al.  Cancer Epigenetics, Tumor Immunity, and Immunotherapy. , 2020, Trends in cancer.

[55]  J. Cuzick,et al.  Key steps for effective breast cancer prevention , 2020, Nature Reviews Cancer.

[56]  N. Restifo,et al.  Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. , 2020, Cancer cell.

[57]  Ceshi Chen,et al.  SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR , 2020, Advanced science.

[58]  T. Phan,et al.  The dormant cancer cell life cycle , 2020, Nature Reviews Cancer.

[59]  R. Bergmann,et al.  Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers , 2020, Journal of experimental & clinical cancer research : CR.

[60]  N. Xia,et al.  EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo , 2020, Clinical & translational immunology.

[61]  Z. Eshhar,et al.  Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. , 2020, Cancer letters.

[62]  H. Einsele,et al.  Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer , 2020, Journal for ImmunoTherapy of Cancer.

[63]  Michael L. Wang,et al.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.

[64]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[65]  R. Franco,et al.  Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. , 2020, Seminars in cancer biology.

[66]  Z. Eshhar,et al.  Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach , 2020, Cancer Immunology, Immunotherapy.

[67]  M. Götte,et al.  Induction of heparanase via IL-10 correlates with a high infiltration of CD163+ M2-type tumor-associated macrophages in inflammatory breast carcinomas , 2020, Matrix biology plus.

[68]  Howard Y. Chang,et al.  CRISPR-engineered T cells in patients with refractory cancer , 2020, Science.

[69]  Jennifer A. Doudna,et al.  THE PROMISE AND CHALLENGE OF THERAPEUTIC GENOME EDITING , 2020, Nature.

[70]  J. Szöllősi,et al.  A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts , 2020, International journal of molecular sciences.

[71]  R. Jain,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[72]  L. Quintanilla‐Martinez,et al.  GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells , 2019, Oncoimmunology.

[73]  K. Kessenbrock,et al.  Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics , 2019, Science Immunology.

[74]  P. Adusumilli,et al.  Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. , 2019, Cancer cell.

[75]  S. T. Eblen,et al.  HUNK phosphorylates EGFR to regulate breast cancer metastasis , 2019, Oncogene.

[76]  N. Ashley,et al.  Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease , 2019, Nature Communications.

[77]  N. Erez,et al.  NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis , 2019, Nature Communications.

[78]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[79]  M. Gnant,et al.  Breast cancer , 2019, Nature Reviews Disease Primers.

[80]  H. Einsele,et al.  ROR1-CAR T-cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. , 2019, JCI insight.

[81]  M. Bachmann.  The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. , 2019, Immunology letters.

[82]  E. King,et al.  Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer , 2019, The Journal of experimental medicine.

[83]  X. Zhang,et al.  Metastasis Organotropism: Redefining the Congenial Soil. , 2019, Developmental cell.

[84]  S. Jagannath,et al.  Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma , 2019, The New England journal of medicine.

[85]  C. June,et al.  Emerging Cellular Therapies for Cancer. , 2019, Annual review of immunology.

[86]  Nikhil S. Joshi,et al.  Treg cell IL-10 and IL-35 exhaust CD8+ T cells in tumors , 2019, Nature Immunology.

[87]  Xin Hu,et al.  Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. , 2019, Cancer cell.

[88]  M. Porteus,et al.  A New Class of Medicines through DNA Editing , 2019, The New England journal of medicine.

[89]  Suna Wang,et al.  Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer , 2019, Journal of Hematology & Oncology.

[90]  J. Visvader,et al.  Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer , 2019, Nature Communications.

[91]  S. Karam,et al.  Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment , 2019, Front. Immunol..

[92]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[93]  D. Mangieri,et al.  Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[94]  D. Ann,et al.  IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype , 2019, Cancer Immunology Research.

[95]  S. Batra,et al.  Cancer-associated mucins: role in immune modulation and metastasis , 2019, Cancer and Metastasis Reviews.

[96]  M. Smyth,et al.  Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.

[97]  Xiaojing Ma,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions , 2018, Cancer Immunology, Immunotherapy.

[98]  Åsa K. Björklund,et al.  Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing , 2018, Nature Communications.

[99]  S. Endres,et al.  Teaching an old dog new tricks: next-generation CAR T cells , 2018, British Journal of Cancer.

[100]  Elvira Khialeeva,et al.  Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory , 2018, Proceedings of the National Academy of Sciences.

[101]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[102]  Jens Pietzsch,et al.  Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells , 2018, Blood Cancer Journal.

[103]  P. Carmeliet,et al.  Phenotype molding of stromal cells in the lung tumor microenvironment , 2018, Nature Medicine.

[104]  A. Thakur,et al.  Bispecific antibody based therapeutics: Strengths and challenges. , 2018, Blood reviews.

[105]  Dorothy Abshire,et al.  The Evolution of Radiation Therapy in Treating Cancer. , 2018, Seminars in oncology nursing.

[106]  B. Sacchetti,et al.  CAR-T cells: the long and winding road to solid tumors , 2018, Cell Death & Disease.

[107]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[108]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[109]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[110]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[111]  A. DeMichele,et al.  Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer , 2017, Cancer Immunology Research.

[112]  G. Doherty,et al.  Activating HER2 mutations as emerging targets in multiple solid cancers , 2017, ESMO Open.

[113]  Stuart A. Sievers,et al.  Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[114]  Elena Butturini,et al.  Metastatic Breast Cancer Cells Enter Into Dormant State and Express Cancer Stem Cells Phenotype Under Chronic Hypoxia , 2017, Journal of cellular biochemistry.

[115]  M. Shipp,et al.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  I. Astsaturov,et al.  Perspectives of HER2-targeting in gastric and esophageal cancer , 2017, Expert opinion on investigational drugs.

[117]  Xiangjian Luo,et al.  Emerging roles of lipid metabolism in cancer metastasis , 2017, Molecular Cancer.

[118]  N. Harbeck,et al.  Breast cancer , 2017, The Lancet.

[119]  T. Seiwert,et al.  Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  L. J. K. Wee,et al.  Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors , 2017, Nature Genetics.

[121]  Kyoung Joo Lee,et al.  Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer , 2017, Oncotarget.

[122]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[123]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[124]  D. Jaffray,et al.  Radiotherapy for Cancer: Present and Future. , 2017, Advanced drug delivery reviews.

[125]  Samuel A. Williams,et al.  A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions , 2017, Science Translational Medicine.

[126]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy , 2016, Cell Research.

[127]  P. Porter,et al.  Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues , 2016, Clinical Cancer Research.

[128]  L. Hurton,et al.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells , 2016, Proceedings of the National Academy of Sciences.

[129]  I. Pastan,et al.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[131]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[132]  G. Ehninger,et al.  Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts , 2016, Blood Cancer Journal.

[133]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[134]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[135]  Yukio Fujiwara,et al.  Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. , 2016, Advanced drug delivery reviews.

[136]  Yu-Sun Chang,et al.  Expression of ROR1 has prognostic significance in triple negative breast cancer , 2016, Virchows Archiv.

[137]  E. Perez,et al.  N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. , 2016, Clinical breast cancer.

[138]  David L. Vaux,et al.  Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies , 2016, Nature Reviews Cancer.

[139]  Yu Cao,et al.  Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies , 2016, Proceedings of the National Academy of Sciences.

[140]  Morgan L. Maeder,et al.  Genome-editing Technologies for Gene and Cell Therapy , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[141]  J. Borg,et al.  The PTK7 and ROR2 Protein Receptors Interact in the Vertebrate WNT/Planar Cell Polarity (PCP) Pathway* , 2015, The Journal of Biological Chemistry.

[142]  C. Dang,et al.  MYC, Metabolism, and Cancer. , 2015, Cancer discovery.

[143]  Minghua Wu,et al.  PTK7 regulates Id1 expression in CD44-high glioma cells. , 2015, Neuro-oncology.

[144]  A. Dirican,et al.  Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[145]  P. Timpson,et al.  FAK signaling in human cancer as a target for therapeutics. , 2015, Pharmacology & therapeutics.

[146]  Emanuela M. Ghia,et al.  Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy , 2014, Proceedings of the National Academy of Sciences.

[147]  S. Riddell,et al.  Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.

[148]  Yongxiang Yin,et al.  PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis. , 2014, International journal of clinical and experimental pathology.

[149]  K. Tracey,et al.  HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. , 2014, Cancer research.

[150]  Eunyoung Kang,et al.  High EGFR gene copy number predicts poor outcome in triple-negative breast cancer , 2014, Modern Pathology.

[151]  F. Penault-Llorca,et al.  Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[152]  Jin Zhu,et al.  ROR1 expression correlated with poor clinical outcome in human ovarian cancer , 2014, Scientific Reports.

[153]  C. Ripp,et al.  The PTK7-Related Transmembrane Proteins Off-track and Off-track 2 Are Co-receptors for Drosophila Wnt2 Required for Male Fertility , 2014, PLoS genetics.

[154]  B. Yao,et al.  Protein Tyrosine Kinase 7 (PTK7) as a Predictor of Lymph Node Metastases and a Novel Prognostic Biomarker in Patients with Prostate Cancer , 2014, International journal of molecular sciences.

[155]  Umar Mahmood,et al.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.

[156]  Ji-Hee Kim,et al.  Protein tyrosine kinase 7 plays a tumor suppressor role by inhibiting ERK and AKT phosphorylation in lung cancer. , 2014, Oncology reports.

[157]  S. Gottschalk,et al.  Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.

[158]  H. Handa,et al.  Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.

[159]  Anita Gandhi,et al.  Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients , 2013, PloS one.

[160]  M. Manns,et al.  Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[161]  W. Eiermann,et al.  PTK7 expression in triple-negative breast cancer. , 2013, Anticancer research.

[162]  M. Smyth,et al.  Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells , 2013, Clinical Cancer Research.

[163]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  P. Tam,et al.  Inhibition of TGF-β signaling in combination with TLR7 ligation re-programs a tumoricidal phenotype in tumor-associated macrophages. , 2013, Cancer letters.

[165]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[166]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[167]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[168]  C. Beadling,et al.  Cytokine-mediated programmed proliferation of virus-specific CD8(+) memory T cells. , 2013, Immunity.

[169]  P. Jänne,et al.  Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. , 2013, Cancer research.

[170]  N. Tolwinski,et al.  The many roles of PTK7: a versatile regulator of cell-cell communication. , 2012, Archives of biochemistry and biophysics.

[171]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[172]  Tomoya Yamaguchi,et al.  NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. , 2012, Cancer cell.

[173]  Donald E Ingber,et al.  Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. , 2012, The Journal of clinical investigation.

[174]  N. Tolwinski,et al.  PTK7/Otk interacts with Wnts and inhibits canonical Wnt signalling , 2011, The EMBO journal.

[175]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[176]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[177]  Elo Leung,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[178]  W. Barry,et al.  CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. , 2010, Journal of the National Cancer Institute.

[179]  K. Pienta,et al.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. , 2010, Neoplasia.

[180]  G. Garlet,et al.  Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment , 2010, Cancer Immunology, Immunotherapy.

[181]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[182]  Gui-yuan Li,et al.  Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. , 2009, Cancer research.

[183]  M. Clynes,et al.  Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[184]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[185]  P. Chames,et al.  Bispecific antibodies for cancer therapy , 2009, Current opinion in drug discovery & development.

[186]  A. Luini,et al.  Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity , 2009, Breast Cancer Research and Treatment.

[187]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[188]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[189]  Mitchell Ho,et al.  Mesothelin Expression in Human Lung Cancer , 2007, Clinical Cancer Research.

[190]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[191]  Mark W. Kieran,et al.  Identification of fibroblast heterogeneity in the tumor microenvironment , 2006, Cancer biology & therapy.

[192]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[193]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[194]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[195]  M. L. Galloway,et al.  The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies , 2006, Histopathology.

[196]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[197]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[198]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[199]  S. Ferrone,et al.  Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms , 2004, The Journal of cell biology.

[200]  B. Pockaj,et al.  Reduced T-Cell and Dendritic Cell Function Is Related to Cyclooxygenase-2 Overexpression and Prostaglandin E2 Secretion in Patients With Breast Cancer , 2004, Annals of Surgical Oncology.

[201]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[202]  N. Ordóñez.  Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma , 2003, Modern Pathology.

[203]  Umberto Veronesi,et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.

[204]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[205]  P. Beuzeboc,et al.  Targeting HER2 in other tumor types. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[206]  J. Guan,et al.  Role of focal adhesion kinase in integrin signaling. , 1997, The international journal of biochemistry & cell biology.

[207]  H. Heinzl,et al.  Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. , 1996, European journal of cancer.

[208]  P. Itin,et al.  Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[209]  Mike Clarke,et al.  EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS , 1995 .

[210]  C. Pabo,et al.  Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. , 1994, Science.

[211]  M R Suresh,et al.  Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[212]  F. Real,et al.  Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals. , 1986, Science.

[213]  P F Davison,et al.  Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. , 1985, Science.

[214]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[215]  D. Stephany,et al.  Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies , 1984, The Journal of experimental medicine.